{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-067778","form_type":"8-K","ticker":"CTXR","cik":"0001506251","company_name":"Citius Pharmaceuticals, Inc.","filed_at":"2024-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.292519+00:00","generated_at":"2026-05-31T10:01:27.874709+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Citius Pharma Q3 net loss $10.6M; FDA approves LYMPHIR, oncology spin-off begins trading","bullets":["FDA approved LYMPHIR (denileukin diftitox-cxdl) for cutaneous T-cell lymphoma on Aug 12, 2024.","Oncology subsidiary merged with TenX Keane; Citius Oncology (Nasdaq: CTOR) starts trading Aug 13, 2024.","Mino-Lok Phase 3 trial met primary and secondary endpoints; cash $17.9M as of June 30, 2024, with runway through Dec 2024.","Net loss $10.6M ($0.06/sh) for Q3 ended June 30, 2024, vs $8.5M ($0.06/sh) a year ago; R&D expenses $2.8M."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-067778","json":"https://secwatch.observer/filing/0001213900-24-067778.json","markdown":"https://secwatch.observer/filing/0001213900-24-067778.md","text":"https://secwatch.observer/filing/0001213900-24-067778.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506251/000121390024067778/0001213900-24-067778-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506251/000121390024067778/ea0211123-8k_citius.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:01:27.874709+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}